News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Middle East hostilities pushed Brent crude toward $100, lifting European oil stocks.
  • European wholesale gas surged to 2023 peaks, intensifying energy-security concerns and complicating near-term policy choices.
  • Fortum shares jumped 10% after signing a 22-year PPA with Google for up to half of Loviisa nuclear output.
  • Victrex stock rallied after the company raised full-year profit guidance and completed a 10% headcount cut.
  • Beiersdorf shares fell after Deutsche Bank downgraded the stock amid cautious company guidance.
  • AfD's advance toward state power in Saxony-Anhalt alarms Holocaust survivors and heightens Germany political-risk concerns.

Latest Articles

Polar Power Reports $7.9 Million in Pacific Islands Revenue as Repeat Orders Drive Expansion Across Off-Grid and Bad-Grid Power Markets

Polar Power Reports $7.9 Million in Pacific Islands Revenue as Repeat Orders Drive Expansion Across Off-Grid and Bad-Grid Power Markets

Polar Power, Inc. announced $7.9 million in revenue from the Pacific Islands since 2024, driven by 333 shipments of DC power and solar-hybrid systems to countries including Papua New Guinea and Fiji. Repeat orders from telecommunications customers indicate growing adoption and reliability of its technology. The company is now expanding into adjacen…

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals announced Q2 2026 financial results and corporate updates, reporting increased patient and prescriber adoption of its FDA-approved cardiovascular drug CARDAMYST for PSVT, expanded insurance coverage to over 50% of commercially insured lives in the U.S., and initiation of a Phase 3 registrational trial for atrial fibrillati…

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies, announced record-high revenues and adjusted EBITDA for the first half and second quarter of 2026, driven by strong sales growth of its proprietary products like KEDRAB in the U.S., VARIZIG, and HEPAGAM. The company affirmed its 2026 annual financial …

Kornit Digital Reports Second Quarter 2026 Results

Kornit Digital Reports Second Quarter 2026 Results

Kornit Digital Ltd. reported second quarter 2026 financial results with total revenues of $55.3 million, surpassing the high end of guidance. The company achieved positive adjusted EBITDA margin, increased Annual Recurring Revenue (ARR) by 79% year-over-year to $33.8 million, and saw All-Inclusive Click (AIC) revenues more than double. Kornit's dig…

Qintess Commits to a Minimum $6.5 Million Spend on Fusemachines Agentic AI Products and Services Over Three Years

Qintess Commits to a Minimum $6.5 Million Spend on Fusemachines Agentic AI Products and Services Over Three Years

Fusemachines Inc. announced a strategic agreement with South American technology services leader Qintess, who has committed to spend at least $6.5 million on Fusemachines' Agentic AI products and services over the next three years. The partnership aims to integrate Fusemachines' AI technology within Qintess' operations and client offerings, expandi…

SUNation Energy Announces 2026 Second Quarter Results; Continues Cost & Balance Sheet Actions and Merger Process with Suniva, Inc.

SUNation Energy Announces 2026 Second Quarter Results; Continues Cost & Balance Sheet Actions and Merger Process with Suniva, Inc.

SUNation Energy reported its Q2 2026 financial results with a 38% year-over-year decline in consolidated revenue primarily due to the expiration of the federal Section 25D residential solar tax credit. The company focused on cost reductions, balance sheet improvements, and progressed a strategic reverse merger transaction with Suniva, Inc., targeti…

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Sutro Biopharma announced favorable early clinical activity of STRO-004 in its Phase 1 trial demonstrating partial responses and a good safety profile. The company is rapidly progressing dose optimization and plans to initiate additional clinical trials of STRO-006 and dual-payload ADC STRO-227 in 2026. Sutro reported solid cash reserves of $164.3 …

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

LeonaBio announced that its lead drug candidate, lasofoxifene, will be highlighted in several presentations at Dava Oncology's 4th Summit on Breast Cancer. The presentations will emphasize lasofoxifene's potential as a novel treatment for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, including progress in its pivotal Phase 3 EL…

Accelerating European Expansion Through Proven Asset-Light Model, Driving Rapid Overseas Revenue Growth; 2Q2026 Total Revenue Reached RMB231.7 Million, Up 82.2% Year over Year

Accelerating European Expansion Through Proven Asset-Light Model, Driving Rapid Overseas Revenue Growth; 2Q2026 Total Revenue Reached RMB231.7 Million, Up 82.2% Year over Year

WeRide Inc., a leader in autonomous driving technology, reported impressive financial results for Q2 2026 with total revenue rising 82.2% YoY to RMB231.7 million. The company showcased significant overseas expansion, particularly in Europe and the Middle East, and continued improvements in domestic robotaxi operations. Key technology launches inclu…

Fervo Energy Reports Second Quarter 2026 Results

Fervo Energy Reports Second Quarter 2026 Results

Fervo Energy reported its Q2 2026 financial and operational results, highlighting its recent public listing on NASDAQ raising $2.2 billion, progress on its enhanced geothermal Cape Station project including mechanical completion of two GeoBlocks and upcoming commissioning, record drilling achievements, and raised development targets to 1.1 GW by 20…

RedCloud Signs India MOUs to Deploy Its RAID and CORE Engines Targeting 11 Apparel Brands, 25,000+ SKUs and 1,250+ Buyer Points

RedCloud Signs India MOUs to Deploy Its RAID and CORE Engines Targeting 11 Apparel Brands, 25,000+ SKUs and 1,250+ Buyer Points

RedCloud Holdings plc announced two Memoranda of Understanding to deploy its AI-powered RAID and CORE engines in collaboration with Dheer Marketing India Pvt. Ltd. and Klakshya Marketing Pvt. Ltd. targeting apparel, footwear, and lifestyle markets in India. The initiative aims to leverage AI for real-time trade data analysis to improve forecasting,…

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion, Inc. announced a Notice of Allowance from the USPTO for a patent covering their technology to precisely position MR Spectroscopy sampling locations within lumbar discs, enhancing accuracy and efficiency of their Nociscan diagnostic platform for chronic low back pain. This patent expands the company's IP portfolio, aiming to reduce scan va…

Marex Group Limited announces second quarter 2026 results

Marex Group Limited announces second quarter 2026 results

Marex Group Limited reported its preliminary unaudited Q2 2026 financial results showing record revenue of $695.8 million and adjusted profit before tax of $165.9 million, representing 39% and 56% year-on-year growth respectively. The company's diversified platform delivered growth across all business segments including Clearing, Agency and Executi…